Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Oligonucleotide Therapy Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The oligonucleotide therapy market has observed rapid expansion recently. This market is projected to expand from $6.2 billion in 2025 to $6.91 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. Factors contributing to its historical growth include heightened research and development in oligonucleotide synthesis, an increasing need for targeted therapies, advancements in molecular biology methods, an increase in chronic and genetic illnesses, and the initial integration of antisense and aptamer technologies.
The oligonucleotide therapy market is anticipated to experience significant expansion in the upcoming years, projected to reach $10.87 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 12.0%. This growth during the forecast period is attributable to several factors, including the expanding scope of personalized medicine, the incorporation of AI into drug discovery processes, the rise of precision medicine initiatives, the creation of next-generation delivery platforms, and the increasing collaborations between biotechnology and pharmaceutical firms. Key trends expected over this period encompass targeted gene regulation, therapeutics based on RNA interference, the advancement of personalized medicine, sophisticated drug delivery mechanisms, and diagnostics utilizing nucleic acids.
Get A Free Sample Report With In-Depth Market Insights:
Oligonucleotide Therapy Market Growth Factors: What’s Supporting Expansion?
Governmental initiatives supporting research and development in healthcare are projected to drive the future growth of the oligonucleotide therapy market. These initiatives represent specific actions, programs, policies, or projects undertaken by government authorities at local, regional, national, or international levels to address particular issues, achieve set goals, or bring about positive societal changes. A number of government bodies are introducing various healthcare programs to support different facets, including oligonucleotide therapy. For example, in April 2025, the American Medical Association, a US-based professional organization, stated that U.S. health spending climbed 7.5% in 2023, reaching $4.9 trillion, or $14,570 per capita, which exceeded the 4.6% increase observed in 2022. Thus, the government initiatives for research and development in healthcare are indeed fueling the expansion of the oligonucleotide therapy market.
Oligonucleotide Therapy Market Segments: Where Is Growth Concentrated?
The oligonucleotide therapy market covered in this report is segmented –
1) By Type: Antisense Oligonucleotide, Aptamer, Other Types
2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
3) By End User: Hospitals, Research Institutes
Subsegments:
1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides
2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers
3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing
Oligonucleotide Therapy Market Industry Trends: What’s Reshaping Demand?
Leading companies in the oligonucleotide therapy market are prioritizing the development of advanced treatments, such as gene therapies, to address the core reasons behind genetic diseases, improve patient outcomes, and alleviate the long-term burden of care. Gene therapies are sophisticated medical interventions intended to introduce a functional gene into a patient’s cells to compensate for one that is non-functional or mutated. For example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, obtained Food and Drug Administration (FDA) approval for ELEVIDYS. This marks the first-of-its-kind gene therapy for ambulatory pediatric patients diagnosed with Duchenne muscular dystrophy (DMD). It is a single-dose therapy formulated to deliver a gene that codes for a shortened, functional form of dystrophin to muscle cells, with the goal of halting or reversing the disease’s progression.
Oligonucleotide Therapy Market Key Participants And Competitive Landscape
Major companies operating in the oligonucleotide therapy market are Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Evox Therapeutics Ltd., PepGen Ltd.
View The Full Oligonucleotide Therapy Market Report:
Oligonucleotide Therapy Market Geographic Distribution And Regional Opportunities
North America was the largest region in the oligonucleotide therapy market in 2025. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
